FDA Approves Rubrevant Faspro as the Only EGFR-Targeted Therapy That Can Be Administered Once a Month
February 18, 2026
February 18, 2026
RARITAN, New Jersey, Feb. 18 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 17, 2026:
* * *
FDA approves RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Monthly dosing reduces treatment visits while maintaining established safety and efficacy/1,2
Builds on RYBREVANT FASPRO(TM) FDA approval to deliver the simplest and fastest c . . .
* * *
FDA approves RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Monthly dosing reduces treatment visits while maintaining established safety and efficacy/1,2
Builds on RYBREVANT FASPRO(TM) FDA approval to deliver the simplest and fastest c . . .